Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Eli Lilly · Phase 1 · Completed · Enrollment 533

NCT06440980

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)n/rn/rn/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)n/rn/rn/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)n/rn/rn/rn/r

Not shown

  • Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3): endpoint not reported
  • Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2): endpoint not reported
  • Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3): endpoint not reported